Important Notice to Long-Term Shareholders of Medpace Holdings, Inc. (NASDAQ: MEDP); New Era Energy & Digital, Inc. (NASDAQ: NUAI); Skyworks Solutions, Inc. (NASDAQ: SWKS); and Upstart Holdings, Inc. (NASDAQ: UPST): Grabar Law Office Investigates Claims on Your Behalf

Legal scrutiny and missed targets signal real risks for these tech stocks—proceed with caution.

What the company is saying

The companies named—Medpace Holdings, New Era Energy & Digital, Skyworks Solutions, and Upstart Holdings—have each projected a narrative of operational strength and future growth, but are now facing legal challenges alleging that these stories were misleading. Medpace, for example, repeatedly told investors it could achieve a book-to-bill ratio of 1.15 in the second half of 2025, describing backlog cancellations as 'well behaved' and not indicative of business weakness, while allegedly concealing adverse information about elevated cancellation rates. New Era Energy & Digital publicly touted 'tangible progress across all fronts' for its Texas Critical Data Centers project, emphasizing engineering, permitting, and land expansion, and claimed substantial progress toward a large-scale AI and high-performance computing campus in West Texas. Skyworks Solutions emphasized its confidence in expanding its mobile business and leveraging AI, while downplaying risks related to its client base—particularly its dependence on Apple—implying that its relationship with Apple was secure for future iPhone launches. Upstart Holdings promoted the accuracy and growth potential of its Model 22, suggesting it would drive higher loan approvals and reliable revenue guidance for 2025. Across these narratives, the companies used assertive, optimistic language, projecting confidence and downplaying or omitting operational or market risks. Notably, the only named executive is Everett Willard Gray II, CEO of New Era, who is directly implicated in legal action for alleged self-dealing and fraudulent schemes; his involvement signals that the issues reach the highest levels of management. The overall communication style is promotional and forward-looking, with little evidence of caution or acknowledgment of downside risk. These narratives fit a broader investor relations strategy of emphasizing growth, innovation, and resilience, but the legal complaints allege a pattern of selective disclosure and material omissions. Compared to prior communications, the shift is stark: the companies’ earlier optimism is now being challenged by hard numbers and legal scrutiny.

What the data suggests

The disclosed numbers paint a picture of deteriorating financial performance and eroding investor confidence. Medpace’s fourth quarter 2025 results revealed a net book-to-bill ratio of only 1.04, falling well short of the previously touted 1.15 target for the second half of 2025. This miss was immediately punished by the market, with Medpace’s stock price dropping over 15.9% from $530.35 to $446.05 in a single day. New Era Energy & Digital’s stock performance is even more severe: after its IPO, the stock fell 6.9% on December 12, 2025, and then plummeted an additional 41% to close at $2.69 per share on December 29, 2025, following legal action and negative research reports. There is no evidence provided of positive financial momentum for any of the companies; instead, the available data points to missed targets, legal exposure, and rapid value destruction. The gap between the companies’ prior claims and the numbers is significant: for example, Medpace’s actual book-to-bill ratio is materially below guidance, and New Era’s operational progress is called into question by both legal filings and third-party research. There is no evidence that prior targets or guidance have been met; in fact, the opposite is true, with realized results falling short and triggering sharp stock declines. The quality of financial disclosure is poor—key metrics such as backlog cancellation rates, Model 22’s actual performance, or Skyworks’ client concentration are referenced but not quantified, making it difficult to independently verify or compare performance over time. An independent analyst, looking only at the numbers, would conclude that these companies are underperforming relative to their own guidance and that the risk of further downside is elevated.

Analysis

The announcement is a legal notice summarizing allegations of securities fraud and shareholder claims against four companies. The tone is negative, focusing on alleged misrepresentations and subsequent stock price declines. Most claims are either realized (stock price drops, missed guidance, legal actions) or relate to past forward-looking statements that have since been contradicted by actual results. There is no promotional or exaggerated language from the companies themselves in this document; rather, it reports on alleged overstatements and legal proceedings. No large capital outlays or future benefit projections are disclosed in the announcement itself. The gap between narrative and evidence is not due to hype in this announcement, but rather to the alleged prior conduct of the companies, now under legal scrutiny.

Risk flags

• ●Operational risk is high for all four companies, as legal complaints allege that management has misrepresented key business metrics and operational progress. This matters because it calls into question the reliability of any future guidance or operational updates, and suggests that internal controls may be weak.
• ●Financial risk is acute, with Medpace and New Era both experiencing sharp stock price declines (over 15.9% and 41%, respectively) following missed targets and legal developments. This pattern indicates that the market is quick to punish underperformance and that downside volatility is significant.
• ●Disclosure risk is substantial, as the companies have referenced key metrics (such as backlog cancellation rates, Model 22 performance, and client concentration) without providing sufficient quantitative detail for investors to independently assess business health. This lack of transparency increases the likelihood of negative surprises.
• ●Pattern-based risk is evident: each company has a history of making forward-looking statements that are later contradicted by actual results or legal findings. This recurring gap between narrative and reality suggests a systemic issue with credibility and investor communications.
• ●Timeline and execution risk is high, especially for New Era, where claims of progress on capital-intensive projects are not supported by evidence of regulatory filings or permit applications. Investors face the risk that promised benefits are years away or may never materialize.
• ●Legal and regulatory risk is front and center, with ongoing securities fraud class actions and, in New Era’s case, direct legal action by the New Mexico Attorney General. These proceedings can result in costly settlements, fines, or operational restrictions, and create headline risk.
• ●Capital intensity risk is flagged for New Era and Skyworks, both of which have referenced large-scale investments (AI data centers, new technology portfolios) without demonstrating clear funding sources or near-term returns. High capital requirements with uncertain payoff increase the risk of dilution or financial distress.
• ●Key person risk is present in New Era, where CEO Everett Willard Gray II is named in legal filings for alleged self-dealing and fraudulent schemes. When the CEO is directly implicated, it raises questions about governance, oversight, and the likelihood of a credible turnaround.

Bottom line

For investors, this announcement signals that all four companies—Medpace, New Era Energy & Digital, Skyworks Solutions, and Upstart Holdings—are facing serious legal and operational headwinds that have already translated into sharp stock price declines and missed performance targets. The credibility of management’s prior claims is now in doubt, as actual results have fallen short and legal complaints allege material misrepresentations and omissions. The involvement of a named CEO (Everett Willard Gray II of New Era) in alleged fraudulent schemes is particularly concerning, as it suggests governance failures at the highest level; however, the presence of a notable individual does not guarantee institutional support or a positive outcome for shareholders. To change this assessment, the companies would need to provide detailed, audited disclosures addressing the specific allegations—such as actual permit filings, backlog cancellation rates, or Model 22’s real-world performance—along with evidence of operational milestones achieved. In the next reporting period, investors should watch for: (1) any restatements or updates to guidance, (2) regulatory or legal developments, (3) concrete evidence of project progress (e.g., permits granted, contracts signed), and (4) changes in management or board composition. Given the current evidence, this is not a signal to buy; at best, it is a warning to monitor closely for further deterioration or, if new facts emerge, for signs of stabilization. The single most important takeaway is that these companies’ narratives have been undermined by both numbers and legal action—until transparency and operational delivery improve, risk remains elevated and caution is warranted.

Announcement summary

Grabar Law Office is investigating shareholder claims against Medpace Holdings, Inc. (NASDAQ: MEDP), New Era Energy & Digital, Inc. (NASDAQ: NUAI), Skyworks Solutions, Inc. (NASDAQ: SWKS), and Upstart Holdings, Inc. (NASDAQ: UPST) regarding alleged breaches of fiduciary duty and securities fraud. Medpace is accused of misleading investors about its book-to-bill ratio, with its stock dropping from $530.35 to $446.05 per share (over 15.9%) after disappointing results. New Era allegedly overstated progress on its Texas Critical Data Centers project and faced a 41% stock drop to $2.69 per share after legal action by the New Mexico Attorney General. Skyworks faces allegations of misleading statements about its client base and AI capabilities, with a class action surviving a motion to dismiss. Upstart is accused of overstating the accuracy of its Model 22 and issuing unreliable revenue guidance for 2025.

Disagree with this article?